Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry.

Détails

ID Serval
serval:BIB_F91877D1FDCE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry.
Périodique
British journal of haematology
Auteur(s)
Hohloch K., Windemuth-Kieselbach C., Kolz J., Zinzani P.L., Cacchione R., Jurczak W., Bischof Delaloye A., Trümper L., Scholz C.W.
ISSN
1365-2141 (Electronic)
ISSN-L
0007-1048
Statut éditorial
Publié
Date de publication
03/2019
Peer-reviewed
Oui
Volume
184
Numéro
6
Pages
949-956
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
To assess efficacy of radioimmunotherapy (RIT) in follicular lymphoma, data from 281 patients collected in the RIT Network, with a median follow-up of 8·2 years after RIT were analysed. RIT was given at first line in 18·5% and at relapse in 81·5%. Following first line therapy, 76·9% achieved complete remission (CR), 9·6% partial remission (PR), 1·9% stable disease (SD) and 1·9% had progressive disease (PD); response was not documented in 9·7%. At relapse, the rate of CR was 48·5% and that of PR was 16·6%, SD 2·6% and PD 10·5%; response was not documented in 21·8%. After median follow-up of 8·2 years, median progression-free survival (PFS) for all was 2·54 years, median overall survival (OS) was not reached. Median PFS and OS (both not reached) were significantly better in first line, compared to RIT at relapse (PFS, 2·11 years; OS, 10·8 years; P = 0·0037 and P = 0·0021, respectively). Overall 8-year PFS was 33·9%, 53·6% for first line and 29·6% for relapsed individuals. Overall 8-year OS was 58·8%, 78·1% for first line and 54·5% for relapsed patients. Thirty-five patients (12·5%) developed secondary malignancy and 16 patients (5·7%) experienced transformation into aggressive lymphoma. RIT is a safe and effective treatment option for follicular lymphoma, both at front line and relapse with an 8-year PFS of 53·6% and 29·6%, respectively.
Mots-clé
Adult, Aged, Aged, 80 and over, Female, Humans, Lymphoma, Follicular/radiotherapy, Male, Middle Aged, Neoplasm Recurrence, Local, Radioimmunotherapy, Registries, Time Factors, Treatment Outcome, first line treatment, follicular lymphoma, late toxicity, long-term follow-up, radioimmunotherapy
Pubmed
Web of science
Création de la notice
13/12/2018 16:37
Dernière modification de la notice
05/04/2020 6:26
Données d'usage